Uniting Awareness and Innovation: Advancing Next-Generation Therapies for Breast Cancer

October 8, 2025

Every year, millions of people around the world are diagnosed with breast cancer, making it the most common cancer among women globally. Unfortunately, there is no single breast cancer therapy that works for all patients – and sometimes, cancer can change and no longer be treated effectively with a specific medicine.

That is why Pfizer is committed to expanding its breast cancer portfolio – creating a range of new, potentially safer and more effective therapies – to help people with cancer live better and longer lives.

How Pfizer is Innovating to Expand its Breast Cancer Portfolio

Across the breast cancer spectrum, Pfizer’s Oncology team is advancing a wide range of potentially transformative therapies to help address unmet patient needs and drive growth for our Oncology business. These efforts include:

Exploring potential label expansion opportunities for approved medicines, like IBRANCE, to treat different sub-types of breast cancer.
Progressing the development of atirmociclib, an investigational medicine which selectively disrupts cancer cell progression and has the potential to become a new best-in-class therapy for frontline and early breast cancer treatment, if successful in clinical trials and approved.
Advancing our pipeline of novel therapeutic agents that have the potential both to create deeper and more durable responses and to address resistance mechanisms to existing treatments.

For more information on Pfizer’s breast cancer portfolio and pipeline, check out our recent Pfizer Pflash. Read more here.

Building on our Legacy of Breast Cancer Innovation

Pfizer has a strong legacy of driving innovative breakthroughs to help treat breast cancer. This past February marked 10 years since our groundbreaking therapy, IBRANCE, became the first FDA-approved CDK 4/6 inhibitor and the cornerstone of our breast cancer franchise. Since then, the therapy has been prescribed to over 838,000 patients and approved in 108 countries.

Today, Pfizer has several approved targeted medicines for certain subtypes of breast cancer – and we are building on our history of breast cancer research and innovation to transform outcomes for patients in what remains one of the most critical areas of oncology.

With the global breast cancer market projected to double to $60 billion by 2030¹, Pfizer is uniquely positioned to advance the future of breast cancer treatment through our R&D strength, innovative approaches to clinical trials, and global scale.

¹Clarivate (DRG) Market Forecast (2023).

Forward-looking statements included herein and in the linked content, including those related to our anticipated operating and financial performance, our research and development strategy and productivity, our product and pipeline advancements and candidates, and our capital allocation strategy and dividend, are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.

Forward-looking statements included herein are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.

Copyright © 2002 – 2025 Pfizer Investor Insights All rights reserved. This information—including product information—is intended only for residents of the United States. The products discussed herein may have different labeling in different countries. This website contains certain information about Pfizer, but may not contain all information that is material to Pfizer.